ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Takeda gets approval for use of dengue inoculation in Indonesia

Japanese pharma to be first to sell vaccine abroad, with other markets planned

Takeda's vaccine against dengue fever was approved in Indonesia on Aug. 23, making it the first Japanese company to be able to sell such a vaccine abroad.   © Reuters

TOKYO (Kyodo) -- Takeda Pharmaceutical Co., Japan's biggest drug maker, said Tuesday that its vaccine for dengue fever had been approved in Indonesia, apparently making it the first Japanese company to sell a vaccine abroad.

The medical group, which has lagged behind in COVID-19 vaccine development, said it is also applying for approval of its inoculation against dengue fever in Asian and South American countries as well as in the European Union, aiming to push its annual sales up to $1.6 billion.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more